Agios Pharmaceuticals (AGIO) Projected to Post Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is expected to post its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect Agios Pharmaceuticals to post earnings of ($1.94) per share and revenue of $10.4890 million for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:00 AM ET.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.19). The company had revenue of $12.50 million during the quarter, compared to analysts’ expectations of $9.46 million. Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. On average, analysts expect Agios Pharmaceuticals to post $-7 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Agios Pharmaceuticals Stock Up 0.8%

AGIO opened at $43.43 on Wednesday. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of 3.95 and a beta of 0.83. Agios Pharmaceuticals has a twelve month low of $23.42 and a twelve month high of $62.58. The company’s 50-day moving average price is $39.27 and its two-hundred day moving average price is $35.50.

Analyst Ratings Changes

A number of research analysts have weighed in on AGIO shares. Bank of America dropped their target price on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating on the stock in a research note on Tuesday, July 22nd. Scotiabank dropped their target price on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating on the stock in a research note on Monday, July 28th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, October 8th. Zacks Research cut shares of Agios Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, October 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $56.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, September 4th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $57.25.

Insider Activity

In other news, CEO Brian Goff sold 11,085 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $36.67, for a total value of $406,486.95. Following the sale, the chief executive officer owned 123,528 shares of the company’s stock, valued at $4,529,771.76. The trade was a 8.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Cecilia Jones sold 3,651 shares of the business’s stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $36.77, for a total transaction of $134,247.27. Following the completion of the sale, the chief financial officer directly owned 33,870 shares in the company, valued at approximately $1,245,399.90. This trade represents a 9.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 23,482 shares of company stock valued at $864,025 over the last quarter. Company insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. NewEdge Advisors LLC bought a new stake in Agios Pharmaceuticals during the 1st quarter worth approximately $40,000. Acadian Asset Management LLC bought a new stake in Agios Pharmaceuticals during the 1st quarter worth approximately $133,000. Tower Research Capital LLC TRC increased its holdings in Agios Pharmaceuticals by 634.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,440 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 5,563 shares during the period. Norges Bank bought a new stake in Agios Pharmaceuticals during the 2nd quarter worth approximately $225,000. Finally, Cerity Partners LLC bought a new stake in Agios Pharmaceuticals during the 2nd quarter worth approximately $226,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.